Trinity Biotech Partners with Latch Medical to Combine CGM+ Biosensor with Precision Drug Delivery
TRIB is trading near its 52-week low of $0.31 (6.2% below the low) on light trading volume (0.1× avg).
Summary
Trinity Biotech announced a strategic collaboration with Latch Medical to integrate its AI-native CGM+ wearable biosensor platform with Latch's Pharma Latch intradermal drug delivery technology. The partnership aims to develop precision therapeutic solutions for diabetes, obesity, and other metabolic conditions by using real-time metabolic data to guide drug delivery. Trinity also plans a strategic equity investment in Latch Medical, backed by its largest investor Perceptive Advisors. This move expands CGM+ beyond monitoring into an integrated metabolic health platform, potentially opening new revenue streams. The announcement follows recent positive CGM+ clinical trial data on nocturnal compression lows. However, the company remains under severe financial pressure with a going concern warning and a reverse split effective July 24, which tempers the near-term impact.
At the time of this announcement, TRIB was trading at $0.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.9M. The 52-week trading range was $0.31 to $3.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.